-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Yidu Tech Inc. (HKG:2158) Is Expected To Breakeven In The Near Future
Yidu Tech Inc. (HKG:2158) Is Expected To Breakeven In The Near Future
With the business potentially at an important milestone, we thought we'd take a closer look at Yidu Tech Inc.'s (HKG:2158) future prospects. Yidu Tech Inc. provides healthcare solutions built on big data and artificial intelligence technologies in Mainland China, Brunei, and internationally. The HK$5.8b market-cap company announced a latest loss of CN¥762m on 31 March 2022 for its most recent financial year result. The most pressing concern for investors is Yidu Tech's path to profitability – when will it breakeven? We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate.
See our latest analysis for Yidu Tech
Consensus from 5 of the Hong Kong Healthcare Services analysts is that Yidu Tech is on the verge of breakeven. They anticipate the company to incur a final loss in 2024, before generating positive profits of CN¥302m in 2025. Therefore, the company is expected to breakeven roughly 3 years from now. How fast will the company have to grow each year in order to reach the breakeven point by 2025? Working backwards from analyst estimates, it turns out that they expect the company to grow 94% year-on-year, on average, which signals high confidence from analysts. Should the business grow at a slower rate, it will become profitable at a later date than expected.
SEHK:2158 Earnings Per Share Growth September 16th 2022Underlying developments driving Yidu Tech's growth isn't the focus of this broad overview, however, keep in mind that by and large a healthcare tech company has lumpy cash flows which are contingent on the product and stage of development the company is in. This means, large upcoming growth rates are not abnormal as the company is beginning to reap the benefits of earlier investments.
One thing we'd like to point out is that Yidu Tech has no debt on its balance sheet, which is rare for a loss-making healthcare tech company, which usually has a high level of debt relative to its equity. This means that the company has been operating purely on its equity investment and has no debt burden. This aspect reduces the risk around investing in the loss-making company.
Next Steps:
There are key fundamentals of Yidu Tech which are not covered in this article, but we must stress again that this is merely a basic overview. For a more comprehensive look at Yidu Tech, take a look at Yidu Tech's company page on Simply Wall St. We've also compiled a list of essential aspects you should look at:
- Valuation: What is Yidu Tech worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Yidu Tech is currently mispriced by the market.
- Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Yidu Tech's board and the CEO's background.
- Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
由于该业务可能处于重要的里程碑,我们想仔细研究一下 易都科技有限公司's (HKG: 2158) 未来前景。Yidu Tech Inc. 在中国大陆、文莱和国际上提供基于大数据和人工智能技术的医疗保健解决方案。这家市值58亿港元的公司宣布其最新财年业绩于2022年3月31日出现7.62亿元人民币的最新亏损。投资者最紧迫的担忧是宜都科技的盈利之路——何时会实现盈亏平衡?我们简要概述了行业分析师对公司的预期、盈亏平衡年份和隐含增长率。
查看我们对易都科技的最新分析
5位香港医疗服务分析师的共识是,宜都科技正处于盈亏平衡的边缘。他们预计该公司将在2024年出现最终亏损,然后在2025年产生3.02亿元人民币的正利润。因此,预计该公司将在大约3年后实现盈亏平衡。公司每年必须以多快的速度增长,才能在2025年之前达到盈亏平衡点?与分析师的估计相反,事实证明,他们预计该公司平均同比增长94%,这表明分析师信心十足。如果业务增长速度放缓,则盈利的日期将晚于预期。
香港交易所:2158 2022 年 9 月 16 日每股收益增长推动Yidu Tech增长的潜在发展并不是本概述的重点,但是请记住,总的来说,医疗科技公司的现金流不稳定,这取决于公司所处的产品和发展阶段。这意味着,即将到来的巨大增长率并不异常,因为该公司已开始从先前的投资中受益。
我们想指出的一件事是,宜都科技的资产负债表上没有债务,这对于一家亏损的医疗科技公司来说是罕见的,相对于其股权而言,债务水平通常很高。这意味着该公司一直纯粹依靠股权投资运营,没有债务负担。这方面降低了投资亏损公司的风险。
后续步骤:
本文未涵盖Yidu Tech的关键基础知识,但我们必须再次强调,这只是一个基本概述。要更全面地了解 Yidu Tech,请查看 Yidu Tech 在 Simply Wall St 上的公司页面。我们还整理了一份你应该关注的基本方面清单:
- 估价: 今天的宜都科技值多少钱?未来的增长潜力是否已经计入了价格?我们免费研究报告中的内在价值信息图有助于直观地了解市场目前是否对益都科技进行了错误的定价。
- 管理小组: 经验丰富的管理团队掌舵增强了我们对业务的信心——看看谁在宜都科技董事会任职以及首席执行官的背景。
- 其他表现优异的股票: 还有其他具有良好往绩的股票前景更好吗?在这里浏览我们的免费这些优质股票清单。
对这篇文章有反馈吗?对内容感到担忧? 取得联系 直接和我们联系。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St 的这篇文章本质上是一般性的。 我们仅使用公正的方法提供基于历史数据和分析师预测的评论,我们的文章无意提供财务建议。 它不构成买入或卖出任何股票的建议,也没有考虑您的目标或财务状况。我们的目标是为您提供由基本面数据驱动的长期重点分析。请注意,我们的分析可能未将最新的价格敏感型公司公告或定性材料考虑在内。简而言之,华尔街对上述任何股票都没有头寸。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧